Graves’ Disease Treatment (Overactive Thyroid): Integrative Care in Mumbai and Online

What is Graves’ disease?

Graves’ disease is an autoimmune disease: the immune system makes antibodies (TSH receptor antibodies, or TRAb) that switch the thyroid on, so it makes more thyroid hormone than the body needs, according to NIDDK [1]. About 4 in every 5 people with an overactive thyroid have Graves’ disease, according to the NHS [8].

• Who gets it: an overactive thyroid is about 10 times more common in women than men and typically starts between 20 and 40 years of age, according to the NHS [8]; for Graves’ disease, the 2018 ETA guideline gives a peak between 30 and 60 [2].
• Genes and family: about 30% of people with Graves’ have a relative with Graves’ or Hashimoto’s, and twin studies suggest that about 80% of the risk is genetic, according to the 2018 ETA guideline [2].
• In India: in a 2013 study of 5,360 adults in 8 cities including Mumbai, 0.67% had an overactive thyroid and 1.27% a mildly overactive (subclinical) thyroid, from any cause; the study measured thyroid function, not Graves’ disease itself [3]. A 2026 review reports that Graves’ in India tends to start at a younger age, affects relatively more men and involves the eyes less often than in white European populations [9]. We found no Indian national guideline for adults with Graves’ disease in October 2026, so Cure4Pain follows the international guidelines named on this page.

What are the symptoms of Graves’ disease?

The main symptoms of an overactive thyroid are nervousness, anxiety and irritability, difficulty sleeping, tiredness, sensitivity to heat, muscle weakness, diarrhoea, a fast or irregular heartbeat, trembling, sweating, weight loss despite a good appetite and a swelling in the neck (goitre), according to the NHS [10].

• Eyes: bulging, gritty or puffy eyes, light sensitivity, pressure or pain in the eyes, or blurred or double vision can be signs of thyroid eye disease (see below), according to NIDDK [1].
• Skin: some people develop reddish, thick skin, usually on the shins (Graves’ dermopathy); most cases are mild and painless [1].
• Heart rhythm: an overactive thyroid can cause an irregular heartbeat (atrial fibrillation); in a Danish study of 40,628 people, 8.3% had atrial fibrillation within 30 days of diagnosis, more often men and older people [11].
• Bones and muscles: an untreated overactive thyroid weakens bone and raises fracture risk; bone density recovers once thyroid levels are brought back to normal, according to a 2003 meta-analysis [12].

What causes Graves’ disease? Smoking, iodine and other triggers

The cause is a mix of genes and triggers, and the best-supported trigger you can change is smoking: a 2002 meta-analysis found current smokers had 3.3 times the odds of Graves’ disease, and ever smokers 4.4 times the odds of Graves’ eye disease [6].

• Iodine: too much iodine, from kelp, seaweed, iodine supplements, some cough syrups and multivitamins, can cause or worsen an overactive thyroid in people with Graves’, according to NIDDK [1]; iodine contrast for scans and the heart medicine amiodarone can do the same [4][8]. India’s iodised salt gives adequate iodine on average: the 2018-19 India Iodine Survey found adequate iodine levels in women of reproductive age [13].
• After childbirth: the risk of Graves’ relapse is highest in the months after delivery, 25% to 55% according to the 2026 ATA pregnancy guideline [14].
• Stress: a 1991 Swedish study found more stressful life events in the year before diagnosis, but this was a questionnaire-based case-control study, so it shows a link, not a cause [15].
• Other autoimmune diseases: in a UK study of 2,791 people with Graves’, about 1 in 10 had another autoimmune disease, most often rheumatoid arthritis, and people with autoimmune thyroid disease had more than 10 times the expected risk of lupus, coeliac disease and vitiligo [16]. See our Rheumatoid Arthritis and Lupus pages.

How is Graves’ disease diagnosed?

Graves’ disease is diagnosed with blood tests showing a low TSH and high thyroid hormones (free T4 and T3), plus TSH receptor antibodies (TRAb), which the 2018 ETA guideline calls a sensitive and specific test for Graves’ [2]; when the cause is unclear, a radioactive iodine uptake scan or a Doppler ultrasound of thyroid blood flow helps, according to the 2016 ATA guideline [4]. The 2024 South Asian expert recommendations also advise TRAb to tell Graves’ apart from other causes of an overactive thyroid [17].

• Biotin can fake the results: high-dose biotin, found in hair, skin and nail supplements and some B-complex products, can make tests look exactly like Graves’ (low TSH, high free T4 and falsely high TRAb), according to the 2016 ATA and 2026 ETA guidelines; stop biotin before thyroid tests, as advised by your doctor [4][18][19].
• Tests at Cure4Pain: our standard panel of about 100 measures with ANA by the IFA method (our clinic protocol for every autoimmune patient), including TSH, free T4, free T3, TRAb and TPO antibodies, vitamin D, PTH, calcium, kidney and liver function and a full blood count, with your thyroid scan or ultrasound reports. Outside India, tests are done at a laboratory near you and uploaded to our patient portal.

What is the difference between Graves’ disease and Hashimoto’s?

Graves’ disease and Hashimoto’s thyroiditis are both autoimmune thyroid diseases: in Graves’ disease, TSH receptor antibodies switch the thyroid on and make it overactive, while in Hashimoto’s the immune system damages the thyroid, usually making it underactive, according to NIDDK [1][20].

• One condition can follow the other: Hashimoto’s uncommonly changes into Graves’ [21], and Graves’ treated with radioactive iodine or surgery usually leaves the thyroid underactive [4], so thyroid tests continue for life. See our Hashimoto’s Thyroiditis page.

What is the conventional treatment for Graves’ disease? Medicines as per guidelines

According to the 2016 ATA and 2018 ETA guidelines, most people with newly diagnosed Graves’ disease are treated first with an antithyroid medicine, methimazole or carbimazole, for about 12 to 18 months, with a beta blocker for a fast heartbeat and tremor; radioactive iodine or thyroid surgery are the other options [4][2]. The 2019 NICE guideline (updated 2023) offers radioactive iodine as first definitive treatment for many adults, and medicines first when they are likely to control the disease [22].

• Long-term low-dose methimazole: both guidelines allow continuing low-dose methimazole for people who prefer it [4][2]. In a 2019 randomised trial from Iran, 258 people continued methimazole for 5 to 10 years in total or stopped after 18 to 24 months; the overactive thyroid returned within 4 years in 15% of the long-term group and 53% of the standard group [23], with similar results at 7 years [24].
• Radioactive iodine: never used in pregnancy or breastfeeding, and pregnancy is postponed for at least 6 months afterwards, according to the 2018 ETA guideline [2]; it can start or worsen thyroid eye disease, especially in smokers, so steroid cover is advised in people at risk [4][2]. Iodine supplements and seaweed are stopped at least 7 days before [4].
• Surgery: total or near-total thyroidectomy by an experienced thyroid surgeon; the main risks are low calcium from parathyroid injury and voice changes from nerve injury, and the 2016 ATA and 2018 ETA guidelines advise correcting low vitamin D before surgery to reduce the risk of low calcium [4][2].
• Safety on antithyroid medicine: a high temperature, sore throat or persistent cough can be signs of agranulocytosis, a rare drop in white blood cells (0.2% to 0.5%, mostly in the first 3 months): stop the medicine and get a blood count the same day, according to the 2016 ATA guideline and the NHS [4][25]. Yellow skin or eyes, dark urine or pale stools can mean liver injury, which is more serious with PTU [4].
• Remission, as the guidelines define it: the 2016 ATA guideline says a person is in remission when TSH, free T4 and T3 stay normal for 1 year after stopping antithyroid medicine [4]. It does not mean Graves’ has gone away: in a 2017 meta-analysis of 54 studies, 48.7% relapsed after a course of medicine, more often with large goitres, smoking, eye disease and high TRAb [26].
• Subclinical Graves’: a mildly overactive thyroid (low TSH with normal hormones) is treated mainly when TSH is very low in people aged 65 or over or with heart disease, osteoporosis or symptoms, according to the 2016 ATA guideline [4].

At Cure4Pain, Dr Krushal Pabari prescribes and adjusts these medicines as per guidelines, under clinical guidance from Team Cure4Pain, in coordination with your existing consulting physician and endocrinologist; radioactive iodine and surgery are decided with your endocrinologist and thyroid surgeon, and eye treatment with an eye specialist. Supervised vitamin D therapy (Coimbra Protocol-based methods) and the integrative plan are added alongside them, never in place of them; never stop or change your medicines on your own, except that a high temperature or sore throat on antithyroid medicine means stopping it and contacting your doctor for a blood count the same day, as described above.

How does Cure4Pain manage Graves’ disease?

Cure4Pain, an integrative and functional medicine clinic in Malad West, Mumbai, with online consultations worldwide, manages Graves’ disease as a lifelong condition within integrative rheumatology: Dr Krushal Pabari prescribes and adjusts the antithyroid medicines as per guidelines, and the clinic adds supervised vitamin D therapy and a nutritional layer, never in place of standard treatment. We see newly diagnosed and relapsed Graves’, mildly overactive (subclinical) Graves’, people already treated with radioactive iodine or surgery who now take levothyroxine, and thyroid eye disease; thyroid storm and sight-threatening eye disease are treated in hospital first. The plan includes:

1. Assessment first: your thyroid tests, TRAb, scan or ultrasound reports, medicines, and our full blood panel with ANA.
2. Guideline medicines: antithyroid medicines and beta blockers prescribed and adjusted by Dr Krushal Pabari, including long-term low-dose methimazole where you prefer it; radioactive iodine or surgery discussed with your endocrinologist and surgeon.
3. Supervised vitamin D therapy (Coimbra Protocol-based methods): no fixed dose for every person; the dose is set for each person and adjusted to blood tests, never on your own (see below).
4. Selenium: given to everyone with Graves’ as clinic practice, with the dose and duration decided by Dr Krushal Pabari and Team Cure4Pain (see below).
5. Cofactors and nutrients in supervised doses: magnesium, zinc, B vitamins, vitamin K2 and calcium for bone, based on your tests. No iodine supplements.
6. Diet: a balanced home-cooked diet, with enough protein and calories while weight is low and a plan for the weight regain that often follows treatment (see below).
7. Eyes: stopping smoking, eye comfort measures, and referral to an eye specialist when needed.
8. Gut health: gut protocols managed by Dr Krushal Pabari where tests show a need.
9. Mind and sleep: lifestyle counselling for sleep and stress at every visit, and our in-house psychiatrist for anxiety or low mood when needed.
10. Exercise: gentle activity until the heartbeat and thyroid levels are controlled, then resistance training for muscle and bone, delivered by a local physiotherapist who reports back to us.
11. Monitoring: thyroid tests every 4 to 6 weeks at the start, TRAb before stopping medicine, blood count and liver tests as the guidelines advise, and the full panel with ANA every 6 to 8 weeks (clinic protocol), which is mandatory during vitamin D therapy; bone density scans where needed.

We do not offer acupuncture or needling for Graves’ disease.

Does vitamin D help Graves’ disease? What the research shows

Vitamin D has not been shown to help Graves’ disease: in the 2023 DAGMAR trial in Denmark, 278 adults starting antithyroid medicine took a daily vitamin D supplement or a placebo, and the trial’s measure of failure (not being able to stop medicine, or relapse within 12 months of stopping it) was 42% with vitamin D and 32% with placebo, a difference that was not statistically significant; the authors concluded that high-dose vitamin D supplementation “cannot be recommended” for Graves’ disease [7].

• What the guidelines say: the 2016 ATA and 2018 ETA guidelines advise correcting low vitamin D before thyroid surgery [4][2]; they do not recommend vitamin D as a treatment for Graves’ disease.
• What this means: vitamin D is not a replacement for antithyroid medicine. No study of the Coimbra Protocol or of very high daily doses in Graves’ disease or thyroid eye disease was found in our PubMed search in October 2026. At Cure4Pain, vitamin D is used alongside guideline treatment, under supervision, as one therapy among several; individual results vary and further studies are needed.

What is the Coimbra Protocol, and how does Cure4Pain use it in Graves’ disease?

The Coimbra Protocol is a method of high-dose vitamin D therapy for autoimmune conditions, developed by Dr Cicero Galli Coimbra in Brazil, in which doses are adjusted to blood tests alongside a strict low-calcium diet and at least 2.5 litres of fluid a day [32]. Our methods are derived from the work of Dr Coimbra, and we give the Coimbra Protocol full credit. For Graves’ disease, Cure4Pain uses supervised vitamin D therapy (Coimbra Protocol-based methods): there is no fixed dose for every person or condition, and the dose is set for each person by clinical judgement and adjusted to blood tests. No trial of the Coimbra Protocol in Graves’ disease was found in our PubMed search in October 2026, and it is not part of Graves’ guidelines. Dr Krushal Pabari and AT. Chintan Dalal, N.D. apply these methods within an integrative rheumatology practice that manages medicines and drug interactions, with detailed blood monitoring. See our Coimbra Protocol page.

How is vitamin D therapy monitored for safety?

High doses of vitamin D can raise blood calcium and harm the kidneys, according to the US National Institutes of Health [33]. In a 2022 study of 319 people with autoimmune diseases treated with high-dose vitamin D under the Coimbra Protocol, with a strict low-calcium diet and at least 2.5 litres of fluid a day, average calcium and kidney results stayed within normal ranges for up to 3.5 years; the study was retrospective, came from one centre in Germany, had no comparison group and did not name Graves’ among its conditions [32].

• Official limit: the upper limit for vitamin D without medical supervision is 1,000 to 4,000 IU a day depending on age, according to the US National Institutes of Health [33].
• Calcium in Graves’: an overactive thyroid can raise blood calcium and lower bone density [12], so calcium is checked closely during vitamin D therapy.
• At Cure4Pain: the full panel, including vitamin D, calcium, PTH and kidney function, is mandatory every 6 to 8 weeks, and doses are adjusted to the results. Please never copy doses from the internet, from forums or from videos.

Does selenium help Graves’ disease and the eyes?

Selenium has trial evidence in mild thyroid eye disease: in a 2011 randomised trial in the New England Journal of Medicine, 159 people with mild Graves’ eye disease who took selenium for 6 months had better quality of life and less eye involvement than with placebo [34], and the 2022 ATA and ETA consensus says a single 6-month course of 100 mcg of selenium twice a day may be considered for mild, active thyroid eye disease, particularly where selenium intake is low [35].

• For the overactive thyroid itself: a 2018 meta-analysis of 10 trials found that selenium added to antithyroid medicine lowered thyroid hormones a little at 3 and 6 months but not at 9 months, and its effect on remission (normal TSH, free T4 and T3 for 1 year after stopping medicine, as the 2016 ATA guideline defines it) is not proven [36]; the Graves’ guidelines do not recommend it for this.
• Newer evidence: a 2026 meta-analysis of 5 trials confirmed lower eye disease activity but found no consistent benefit for quality of life or vision, and called for larger trials [37].
• At Cure4Pain: as clinic practice, selenium is given to everyone with Graves’ disease, and the dose and duration for each person are decided by Dr Krushal Pabari and Team Cure4Pain. Too much selenium can cause hair loss, brittle nails, a garlic smell on the breath and a metallic taste, according to the US National Institutes of Health [38], so please do not add selenium on your own.

What is thyroid eye disease, and how is it treated?

Thyroid eye disease (Graves’ orbitopathy) is inflammation of the tissues around the eyes that can cause bulging, gritty or red eyes, swollen lids and double vision; a 2020 meta-analysis of 57 studies and 26,804 people found it in 40% of people with Graves’, 44% in Asia [5]. Stopping smoking is the most important step: the 2016 ATA guideline calls smoking the most important known risk factor for developing or worsening it [4].

• Mild eye disease: lubricating eye drops, sunglasses for light sensitivity, sleeping with the head raised for puffy lids [1], stopping smoking (and avoiding second-hand smoke), keeping thyroid levels steady, and selenium for 6 months, according to the 2021 EUGOGO guideline and the 2022 ATA and ETA consensus [39][35].
• Moderate to severe eye disease: specialist treatment with steroids given into a vein, with or without mycophenolate (EUGOGO’s first choice), or teprotumumab (the ATA and ETA’s first choice for many people), with tocilizumab, rituximab, orbital radiotherapy or surgery in some cases [39][35][40]. In trials, mycophenolate with steroids helped 71% against 53% with steroids alone [41], and teprotumumab reduced eye bulging in 83% against 10% with placebo [42]; teprotumumab can affect hearing, with clinically significant hearing problems in about 8% in a 2026 meta-analysis, so hearing tests are advised [43].
• In India: in a 2020 study of 301 Indian patients with thyroid eye disease, 19% had sight-affecting complications needing steroid treatment, more often men, older people and people with diabetes [44].
• At Cure4Pain: eye treatment is decided with an eye specialist (an oculoplastic or orbit specialist); we support it with stopping smoking, selenium and steady thyroid control.

Which vitamins and minerals matter in Graves’ disease?

The best-supported nutrient points in Graves’ are avoiding excess iodine, as NIDDK advises [1], and protecting the bones, which recover once thyroid levels are normal [12].

• Iodine: Cure4Pain does not give iodine supplements in Graves’ disease. Avoid kelp, seaweed and iodine drops [1]; normal iodised salt in cooking is fine.
• Magnesium: magnesium is needed by the enzymes that activate and break down vitamin D, and in a 2018 randomised trial in adults without Graves’, magnesium supplements changed vitamin D levels [45]; we found no trial of magnesium in Graves’. The upper limit from supplements is 350 mg a day for adults, and magnesium can loosen stools [46].
• Vitamin K2: used with vitamin D as clinic practice for bone; we found no trial in Graves’. Vitamin K can interfere with blood thinners such as warfarin [47].
• Zinc and B vitamins: given based on your tests, as clinic practice.
• Ashwagandha: avoid it. The US National Center for Complementary and Integrative Health says it is not recommended for people with thyroid or autoimmune disorders [48], and a 2022 case report describes an overactive thyroid caused by it [49].

What should you eat with Graves’ disease?

No Graves’ guideline sets a special diet; the evidence-based diet point is avoiding excess iodine from seaweed, kelp and iodine supplements, according to NIDDK [1], and a 2022 review in the Journal of Clinical Endocrinology & Metabolism found little proven benefit in avoiding cruciferous vegetables or soy, and that avoiding gluten or dairy helps only people with a matching intolerance [50].

• At Cure4Pain: a balanced diet of home-cooked meals, planned differently for vegetarians and non-vegetarians, avoiding processed foods and breads; dairy is reduced where it does not suit you, and during vitamin D therapy calcium intake is managed within a limit set for you.
• Weight: most people lose weight while the thyroid is overactive, and many regain it after treatment, sometimes more than they lost, according to a 2019 review [51]; the plan gives enough protein and calories at first and adjusts as thyroid levels settle.
• Cruciferous vegetables (cabbage, cauliflower, broccoli): as an observational clinic practice, we generally suggest limiting them. A 2024 systematic review of 123 studies found that eating these vegetables, particularly with adequate iodine, has no adverse effect on thyroid function [52]. Our advice is a clinic precaution, not a research finding.
• Gluten: coeliac disease is more common in overactive autoimmune thyroid disease (2.6% in a 2016 meta-analysis) [53]; a gluten-free diet is for people with coeliac disease or gluten sensitivity [50].
• Before radioactive iodine: stop iodine supplements and seaweed for at least 7 days; a low-iodine diet is sometimes advised [4].

Can stress, sleep and exercise affect Graves’ disease?

Stress is linked with Graves’ in observational studies only [15], and an overactive thyroid itself causes anxiety, irritability and poor sleep [8], which usually ease as thyroid levels are controlled. No Graves’ guideline gives exercise rules; antithyroid treatment alone improved muscle strength by 25% to 40% in the DAGMAR study [30], and a small 2012 retrospective study of a structured exercise programme reported fewer relapses, which needs confirming in trials [54].

• At Cure4Pain: lifestyle counselling for sleep and stress at every visit, our in-house psychiatrist when needed, gentle activity until the heartbeat and thyroid levels are controlled, then resistance training for muscle and bone with a local physiotherapist (clinic practice).

Can I get pregnant with Graves’ disease?

Yes: the 2026 ATA pregnancy guideline advises planning pregnancy with your endocrinologist once thyroid levels have been normal on two sets of tests, switching from methimazole to PTU while trying to conceive where PTU is available, and using the lowest effective dose, because uncontrolled Graves’ raises the risk of miscarriage, pre-eclampsia and poor baby growth [14]. TRAb is checked in pregnancy because high levels can affect the baby’s thyroid, and methimazole is generally preferred while breastfeeding [14]. The guideline advises 150 mcg of iodine a day for all women before conception, in pregnancy and while breastfeeding [14]; with Graves’ disease, your endocrinologist and obstetrician decide this. At Cure4Pain, pregnancy care is led by your endocrinologist and obstetrician, and vitamin D is given only at standard supplement doses during pregnancy.

Can children get Graves’ disease?

Yes. About 5% of all Graves’ disease starts in childhood, more often in girls, and the 2022 ETA guideline for children recommends methimazole or carbimazole for 3 years or more, never PTU because of the risk of liver failure, with a paediatric endocrinologist involved in all cases [55]. In India, the 2022 Indian Academy of Pediatrics guideline also prefers methimazole or carbimazole and suggests 1 to 2 years of medicine before radioactive iodine or surgery is considered [56]. Dr Krushal Pabari sees children and teenagers with Graves’ together with a paediatric endocrinologist, and vitamin D and all medicines for children are agreed with that specialist.

Is Graves’ disease serious? Outlook

Graves’ disease is a long-term condition that can be controlled with treatment; left untreated, it can cause a rapid and irregular heartbeat that can lead to blood clots, stroke or heart failure, thinning bones, muscle problems and problems with periods, fertility and pregnancy, according to NIDDK [1]. About half of people relapse after a standard course of antithyroid medicine [26], so thyroid tests continue for life, and most people treated with radioactive iodine or surgery need levothyroxine for life [4]. At Cure4Pain, Graves’ disease is lifelong management, with regular monitoring and reviews. See our Hypothyroidism page for life on levothyroxine and our Osteoporosis page for bone health.

When should you get urgent help?

Get emergency help (call 112 in India and Europe, 911 in the US and Canada) for signs of a thyroid storm, a rare emergency: a very fast heartbeat, high temperature, severe agitation or confusion, yellow skin or eyes, or loss of consciousness, according to the NHS [57]. Also get urgent help for bulging eyes with any change in vision, such as wavy lines, flashing or loss of vision, or with severe eye pain or headache [58], and for fever or a sore throat while on antithyroid medicine [25]. Cure4Pain does not treat emergencies.

Which doctor treats Graves’ disease?

People with an overactive thyroid are usually referred to an endocrinologist, a specialist in hormone conditions, who plans treatment, according to the NHS [25]; thyroid eye disease is treated with an eye specialist [35]. At Cure4Pain, Dr Krushal Pabari, whose training is in rheumatic and musculoskeletal diseases, prescribes and adjusts the antithyroid medicines and leads integrative care in Mumbai and online, in coordination with your endocrinologist, thyroid surgeon and eye specialist.

Can I get Graves’ disease care online from outside India?

Cure4Pain sees people with Graves’ disease in person in Mumbai and online from any country, with consultations led by Dr Krushal Pabari.

1. Register your case on our patient portal with your thyroid tests, TRAb, scan or ultrasound reports and medicines.
2. Blood tests near you: the panel is done at a laboratory in your city or country and uploaded to the portal; in India, home collection is available.
3. Consultation online or in Mumbai with Dr Krushal Pabari and AT. Chintan Dalal, N.D.; available appointments are shown on the portal.
4. Ongoing care: regular blood tests and reviews, with your endocrinologist kept in the loop.

How do I book a consultation?

Please register your case on our patient portal with your thyroid blood tests, scan reports and medical history. We take patients on only after reviewing these reports. Consultations are in person in Mumbai or online worldwide. Registrations and appointments are made only through our patient portal.

Evidence: key studies

Who treats you

• Dr Krushal PabariMD, PGCP - Rheumatic & Musculoskeletal Diseases. Assistant Professor, Cooper Hospital; Guest Professor, CMP Homoeopathic Medical College.
• AT. Chintan Dalal, N.D.BNYS, R.AP. Functional nutrition and Coimbra Protocol practitioner.

Consultations look at the whole person: alongside the medical and nutritional plan, we bring a strong interest in behavioural science to counselling on stress, sleep and lasting lifestyle change.

How consultations work: Mumbai or online worldwide

Book through our patient portal. You can see us in person at our clinic in Malad West, Mumbai, or online from anywhere. Your first consultation reviews your history and tests; we then agree a plan together and set the monitoring schedule.

Related conditions and articles

• Hashimoto's ThyroiditisAutoimmune thyroid; antibodies, vitamin D, selenium and thyroid care.
• Hypothyroidism (Underactive Thyroid)Underactive thyroid; vitamin D, B12, iron, diet and thyroid care.
• Osteoporosis & OsteopeniaLow bone density; DEXA, nutrients, strength training and medicine review.
• Rheumatoid ArthritisJoint pain and stiffness; integrative care in coordination with your existing consulting physician.

• Autoimmune and inflammatory conditions
• Coimbra Protocol

This page is for education and does not replace medical advice. Do not start, stop or change any medicine or supplement without medical guidance.

References

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), US National Institutes of Health. Graves’ disease. niddk.nih.gov/health-information/endocrine-diseases/graves-disease

2. Kahaly GJ, et al. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J 2018;7(4):167-186. doi:10.1159/000490384

3. Unnikrishnan AG, et al. Prevalence of hypothyroidism in adults: An epidemiological study in eight cities of India. Indian J Endocrinol Metab 2013;17(4):647-52. doi:10.4103/2230-8210.113755

4. Ross DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229

5. Chin YH, et al. Prevalence of thyroid eye disease in Graves’ disease: A meta-analysis and systematic review. Clin Endocrinol (Oxf) 2020;93(4):363-374. doi:10.1111/cen.14296

6. Vestergaard P. Smoking and thyroid disorders–a meta-analysis. Eur J Endocrinol 2002;146(2):153-61. doi:10.1530/eje.0.1460153

7. Grove-Laugesen D, et al. Effect of Vitamin D Supplementation on Graves’ Disease: The DAGMAR Trial. Thyroid 2023;33(9):1110-1118. doi:10.1089/thy.2023.0111

8. NHS. Overactive thyroid (hyperthyroidism). nhs.uk/conditions/overactive-thyroid-hyperthyroidism

9. Singh SK, et al. Graves’ disease in India: epidemiological, clinical, and genetic differences from Caucasians. Postgrad Med J 2026;102(1207):392-399. doi:10.1093/postmj/qgaf204

10. NHS. Overactive thyroid (hyperthyroidism): symptoms. nhs.uk/conditions/overactive-thyroid-hyperthyroidism/symptoms

11. Frost L, et al. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004;164(15):1675-8. doi:10.1001/archinte.164.15.1675

12. Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk–a meta-analysis. Thyroid 2003;13(6):585-93. doi:10.1089/105072503322238854

13. Jha RK, et al. National and Sub-National Estimates of Household Coverage of Iodized Salt and Urinary Iodine Status among Women of Reproductive Age in India: Insights from the India Iodine Survey, 2018-19. J Nutr 2023;153(9):2717-2725. doi:10.1016/j.tjnut.2023.06.037

14. Korevaar TIM, et al. American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum. Thyroid 2026;36(5):481-544. doi:10.1177/10507256261445624

15. Winsa B, et al. Stressful life events and Graves’ disease. Lancet 1991;338(8781):1475-9. doi:10.1016/0140-6736%2891%2992298-g

16. Boelaert K, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 2010;123(2):183.e1-9. doi:10.1016/j.amjmed.2009.06.030

17. Kalra S, et al. Best practices in the laboratory diagnosis, prognostication, prediction, and monitoring of Graves’ disease: role of TRAbs. BMC Endocr Disord 2024;24(1):274. doi:10.1186/s12902-024-01809-9

18. Campi I, et al. 2026 ETA guideline on interference in immunoassay measurements used in assessment of thyroid function. Eur Thyroid J 2026;15(4). doi:10.1530/ETJ-26-0011

19. Elston MS, et al. Factitious Graves’ Disease Due to Biotin Immunoassay Interference-A Case and Review of the Literature. J Clin Endocrinol Metab 2016;101(9):3251-5. doi:10.1210/jc.2016-1971

20. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), US National Institutes of Health. Hashimoto’s disease. niddk.nih.gov/health-information/endocrine-diseases/hashimotos-disease

21. Vassallo A, et al. Clinical and Ultrasonographic Characterization of the Transition from Hashimoto Thyroiditis to Graves’ Disease: A Long-term Follow-up Study. Endocrine 2026;91(1). doi:10.1007/s12020-026-04582-y

22. National Institute for Health and Care Excellence (NICE). Thyroid disease: assessment and management (NG145), 2019, updated 2023. nice.org.uk/guidance/ng145

23. Azizi F, et al. Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves’ Disease: Results of a Randomized Clinical Trial. Thyroid 2019;29(9):1192-1200. doi:10.1089/thy.2019.0180

24. Azizi F, et al. Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves’ hyperthyroidism: a randomized trial and a risk-scoring model. Endocrine 2024;84(2):577-588. doi:10.1007/s12020-023-03656-5

25. NHS. Overactive thyroid (hyperthyroidism): treatment. nhs.uk/conditions/overactive-thyroid-hyperthyroidism/treatment

26. Struja T, et al. Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur J Endocrinol 2017;176(1):87-97. doi:10.1530/EJE-16-0725

27. Xu MY, et al. Vitamin D and Graves’ disease: a meta-analysis update. Nutrients 2015;7(5):3813-27. doi:10.3390/nu7053813

28. Pang B, et al. Association between serum vitamin D level and Graves’ disease: a systematic review and meta-analysis. Nutr J 2024;23(1):60. doi:10.1186/s12937-024-00960-2

29. Yu Y, et al. A Mendelian randomization study of the effect of serum 25-hydroxyvitamin D levels on autoimmune thyroid disease. Front Immunol 2023;14:1298708. doi:10.3389/fimmu.2023.1298708

30. Grove-Laugesen D, et al. Effects of Supplemental Vitamin D on Muscle Performance and Quality of Life in Graves’ Disease: A Randomized Clinical Trial. Thyroid 2020;30(5):661-671. doi:10.1089/thy.2019.0634

31. Grove-Laugesen D, et al. Changes in bone density and microarchitecture following treatment of Graves’ disease and the effects of vitamin D supplementation. A randomized clinical trial. Osteoporos Int 2024;35(12):2153-2164. doi:10.1007/s00198-024-07241-y

32. Amon U, et al. Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the “Coimbra Protocol”. Nutrients 2022;14(8). doi:10.3390/nu14081575

33. Office of Dietary Supplements, US National Institutes of Health. Vitamin D: Fact Sheet for Health Professionals. ods.od.nih.gov/factsheets/VitaminD-HealthProfessional

34. Marcocci C, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 2011;364(20):1920-31. doi:10.1056/NEJMoa1012985

35. Burch HB, et al. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid 2022;32(12):1439-1470. doi:10.1089/thy.2022.0251

36. Zheng H, et al. Effects of Selenium Supplementation on Graves’ Disease: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2018;2018:3763565. doi:10.1155/2018/3763565

37. Kostadinov N, et al. Efficacy of Selenium Supplementation in Graves’ Orbitopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis. J Clin Med 2026;15(12). doi:10.3390/jcm15124710

38. Office of Dietary Supplements, US National Institutes of Health. Selenium: Fact Sheet for Health Professionals. ods.od.nih.gov/factsheets/Selenium-HealthProfessional

39. Bartalena L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 2021;185(4):G43-G67. doi:10.1530/EJE-21-0479

40. Bartalena L, et al. Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy. Eur Thyroid J 2025;14(6). doi:10.1530/ETJ-25-0318

41. Kahaly GJ, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 2018;6(4):287-298. doi:10.1016/S2213-8587%2818%2930020-2

42. Douglas RS, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med 2020;382(4):341-352. doi:10.1056/NEJMoa1910434

43. Lee SH, et al. Incidence and characteristics of teprotumumab-associated ototoxicity in thyroid eye disease: A systematic review and meta-analysis. Surv Ophthalmol 2026. doi:10.1016/j.survophthal.2026.09.005

44. Gupta R, et al. Visual morbidity in thyroid eye disease in Asian Indian patients. Indian J Ophthalmol 2020;68(8):1622-1627. doi:10.4103/ijo.IJO_2284_19

45. Dai Q, et al. Magnesium status and supplementation influence vitamin D status and metabolism: results from a randomized trial. Am J Clin Nutr 2018;108(6):1249-1258. doi:10.1093/ajcn/nqy274

46. Office of Dietary Supplements, US National Institutes of Health. Magnesium: Fact Sheet for Health Professionals. ods.od.nih.gov/factsheets/Magnesium-HealthProfessional

47. Office of Dietary Supplements, US National Institutes of Health. Vitamin K: Fact Sheet for Health Professionals. ods.od.nih.gov/factsheets/VitaminK-HealthProfessional

48. National Center for Complementary and Integrative Health (NCCIH), US National Institutes of Health. Ashwagandha. nccih.nih.gov/health/ashwagandha

49. Kamal HI, et al. Ashwagandha as a Unique Cause of Thyrotoxicosis Presenting With Supraventricular Tachycardia. Cureus 2022;14(3):e23494. doi:10.7759/cureus.23494

50. Larsen D, et al. Thyroid, Diet, and Alternative Approaches. J Clin Endocrinol Metab 2022;107(11):2973-2981. doi:10.1210/clinem/dgac473

51. Kyriacou A, et al. Weight gain following treatment of hyperthyroidism-A forgotten tale. Clin Obes 2019;9(5):e12328. doi:10.1111/cob.12328

52. Galanty A, et al. Do Brassica Vegetables Affect Thyroid Function?-A Comprehensive Systematic Review. Int J Mol Sci 2024;25(7). doi:10.3390/ijms25073988

53. Roy A, et al. Prevalence of Celiac Disease in Patients with Autoimmune Thyroid Disease: A Meta-Analysis. Thyroid 2016;26(7):880-90. doi:10.1089/thy.2016.0108

54. Cutovic M, et al. Structured exercise program improves functional capacity and delays relapse in euthyroid patients with Graves’ disease. Disabil Rehabil 2012;34(18):1511-8. doi:10.3109/09638288.2012.660599

55. Mooij CF, et al. 2022 European Thyroid Association Guideline for the management of pediatric Graves’ disease. Eur Thyroid J 2022;11(1). doi:10.1530/ETJ-21-0073

56. Indian Academy of Pediatrics. Standard Treatment Guidelines 2022: Hyperthyroidism. iapindia.org/pdf/Ch-078-Hyperthyroidism.pdf

57. NHS. Overactive thyroid (hyperthyroidism): complications. nhs.uk/conditions/overactive-thyroid-hyperthyroidism/complications

58. NHS. Bulging eyes (exophthalmos). nhs.uk/symptoms/bulging-eyes

59. LiverTox, US National Institutes of Health (NIDDK). Antithyroid agents. ncbi.nlm.nih.gov/books/NBK548603

60. Gupta RC, et al. Probable mode of action of sankhapuspi in the management of thyrotoxicosis. Anc Sci Life 1981;1(1):49-57. pubmed.ncbi.nlm.nih.gov/22556461

61. Zen XX, et al. Chinese herbal medicines for hyperthyroidism. Cochrane Database Syst Rev 2007;2007(2):CD005450. doi:10.1002/14651858.CD005450.pub2

62. Rogvi-Hansen B, et al. Acupuncture in the treatment of Graves’ ophthalmopathy. A blinded randomized study. Acta Endocrinol (Copenh) 1991;124(2):143-5. doi:10.1530/acta.0.1240143